These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27725014)

  • 1. Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer.
    Abratt RP
    S Afr Med J; 2016 Sep; 106(10):981-982. PubMed ID: 27725014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.
    Phillips KA; Marshall DA; Haas JS; Elkin EB; Liang SY; Hassett MJ; Ferrusi I; Brock JE; Van Bebber SL
    Cancer; 2009 Nov; 115(22):5166-74. PubMed ID: 19753618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
    Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
    J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline Adherence Regarding the Use of Expensive Drugs in Daily Practice: The Examples of Trastuzumab in Breast Cancer and Bortezomib in Multiple Myeloma.
    Boons CC; Wagner C; Hugtenburg JG
    Oncol Res Treat; 2016; 39(7-8):417-22. PubMed ID: 27486994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
    Lang HC; Chen HW; Chiou TJ; Chan AL
    J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
    Millar JA; Millward MJ
    Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
    Blackwell K; Gligorov J; Jacobs I; Twelves C
    Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer.
    Nixon NA; Hannouf MB; Verma S
    Eur J Cancer; 2018 Jan; 89():72-81. PubMed ID: 29241083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011.
    Chavarri-Guerra Y; St Louis J; Bukowski A; Soto-Perez-de-Celis E; Liedke PER; Symecko H; Moy B; Higgins M; Finkelstein DM; Goss PE
    Breast; 2017 Feb; 31():197-201. PubMed ID: 27894048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
    Leung W; Kvizhinadze G; Nair N; Blakely T
    PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
    Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
    Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
    Cesarec A; Likić R
    Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
    Chen W; Jiang Z; Shao Z; Sun Q; Shen K
    Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.